# Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China.

> PubMed lists PMID 31469303 in Current medical research and opinion as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-09-11 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31469303-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31469303-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-31469303-lixisenatide-v1.json
- Content SHA-256: `f36153643ffaa56490b40c1e5fa26a6036dc0d6371b6780259564c7488d801dd`

## Claims and source pins

### Headline

Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China. ([`pubmed-observation-pmid-31469303-2026-01-27-c9b88cb4cccd`](#source-pubmed-observation-pmid-31469303-2026-01-27-c9b88cb4cccd))

### Summary

PubMed lists PMID 31469303 in Current medical research and opinion as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-09-11 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31469303-2026-01-27-c9b88cb4cccd`](#source-pubmed-observation-pmid-31469303-2026-01-27-c9b88cb4cccd))

### Paragraph 1

PubMed lists PMID 31469303 in Current medical research and opinion as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-09-11 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31469303-2026-01-27-c9b88cb4cccd`](#source-pubmed-observation-pmid-31469303-2026-01-27-c9b88cb4cccd))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31469303-2026-01-27-c9b88cb4cccd`](#source-pubmed-observation-pmid-31469303-2026-01-27-c9b88cb4cccd))

## Sources

<a id="source-pubmed-observation-pmid-31469303-2026-01-27-c9b88cb4cccd"></a>
- **Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China. · retained source version 1:2026-01-27:current:c9b88cb4cccd34ff1e9f51bd0d89801f04163cfe5d267c0df257e280f5d42ea9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31469303/) (`pubmed-observation-pmid-31469303-2026-01-27-c9b88cb4cccd`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-31469303-lixisenatide-v1.json SHA-256: f36153643ffaa56490b40c1e5fa26a6036dc0d6371b6780259564c7488d801dd.